Together with the results from the first randomized controlled study proving the enhanced therapeutic efficiency of fasting mimicking diet in patients with HER2-negative breast carcinoma [13], our data supports the necessity of robust clinical trials to validate the therapeutic benefit of the combined approach and establish dietary recommendations as an adjunct to chemotherapy for triple negative breast cancer treatment. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.